This was the stock's second consecutive day of losses.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.